



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



⑪ Publication number:

0 597 101 A1

⑫

EUROPEAN PATENT APPLICATION  
published in accordance with Art.  
158(3) EPC

⑬ Application number: 92915866.5

⑭ Int. Cl. 5: A61K 39/395

⑯ Date of filing: 17.07.92

⑮ International application number:  
PCT/JP92/00914

⑯ International publication number:  
WO 93/01835 (04.02.93 93/04)

⑰ Priority: 20.07.91 JP 204743/91

⑮ Applicant: HAGIWARA, Hideaki  
4-14; Hiraisanso  
Takarazuka-shi Hyogo 665(JP)

⑯ Date of publication of application:  
18.05.94 Bulletin 94/20

⑯ Inventor: HAGIWARA, Hideaki  
4-14, Hiraisanso  
Takarazuka-shi, Hyogo 665(JP)  
Inventor: YUASA, Hideo  
439-13, Ozaki-cho  
Kasai-shi, Hyogo 675-22(JP)  
Inventor: YAMAMOTO, Yasunori  
5 Iwai Haitsu 721,  
53, Houjyo Mizokawa,  
Houjyo-cho  
Kkasai-shi, Hyogo 675-23(JP)

⑯ Designated Contracting States:  
AT BE CH DE FR GB LI

⑯ Representative: Welsert, Annekäte, Dipl.-Ing.  
Dr.-Ing. et al  
Patentanwälte  
Kraus Welsert & Partner  
Thomas-Wimmer-Ring 15  
D-80539 München (DE)

EP 0 597 101 A1

⑯ STABILIZED HUMAN MONOCLONAL ANTIBODY PREPARATION.

⑯ A stabilized human monoclonal antibody preparation containing 1-20 mg of D-mannitol per milligram of a human monoclonal antibody, which is excellent in the resistance to aggregation and precipitation of a human monoclonal antibody in a dissolved state, a lyophilized state, a frozen state and particularly in a state of redissolution after lyophilization.

Technical Field

This invention relates to a stabilized human monoclonal antibody preparation, and more detailedly, relates to a human monoclonal antibody preparation excellent in stability a solution state, a freeze drying state and a freezing state, particularly redissolution (restoration) stability after freezing drying.

Background Art

Since a process for producing a monoclonal antibody by genetic engineering was proposed in 1975 by 10 Koehler and Milstein [Koehler, G., Milstein, C. *Nature* 256, 495 (1975)], a road has been opened up to supply a large quantity of a monoclonal antibody as a homogeneous antibody, and such monoclonal antibodies have widely been utilized in the medical and biological fields.

Recently, human monoclonal antibodies are provided in human clinical tests, and particularly draw attention in the antitumor-directed medicinal field. However, purified human monoclonal antibodies have an 15 undesirable property as a preparation that they easily aggregate and precipitate in a solution state or at the time of redissolution (restoration) after freeze drying, and development of monoclonal antibody preparations having no such an undesirable property and being stabilized is desired.

On the other hand, as methods for stabilization of antibodies (immunoglobulins), there have hitherto been proposed a method which comprises adding to a sulfonated immunoglobulin serum albumin, or serum 20 albumin with glycine and/or mannitol (Japanese Patent Publication No. 20965/1987); a method which comprises adding a comparatively large quantity of a polyhydric alcohol (Japanese Laid-Open Patent Publication No. 88197/1988); a method which comprises adding dextran (Japanese Laid-Open Patent Publication No. 225320/1988); etc. However, it is impossible, by these so far proposed methods, to improve sufficiently the above undesirable property in human monoclonal antibody preparations.

25 The present inventors now found that stability of a human monoclonal antibody preparation, particularly stability against aggregation and precipitation at the time of redissolution after freeze drying of the human monoclonal antibody is remarkably enhanced by compounding a specified small quantity of mannitol to the human monoclonal antibody, and completed this invention.

30 Disclosure of Invention

Thus, there is provided according to this invention a stabilized human monoclonal antibody preparation containing 1 to 20 mg of D-mannitol per 1 mg of a human monoclonal antibody.

There is no particular limitation on human monoclonal antibodies capable of being stabilized according 35 to this invention, and various human monoclonal antibodies can be used. For example, CLN-IgG, SLN-IgG, CoLN-IgA, TOS/H8-IgM [Hideaki Hagiwara : BIOINDUSTRY, 4, 730 (1987)], etc. can be exemplified as representative examples.

Such a human monoclonal antibody can be made into preparations for putting to practical use as medicinal drugs, etc. As a process for making into a preparation, there can, for example, be mentioned a 40 process which comprises, according to necessity, concentrating a purified human monoclonal antibody by ultrafiltration, sodium sulfate fractionation or the like, substituting a buffer solution suitable for the preparation by a gel filtration method, in some case further adjusting the concentration, making a filtration sterilization processing, and then making freeze drying.

In preparation of a stabilized human monoclonal antibody preparation, it is possible to compound D- 45 mannitol as a stabilizer at any stage of the above making of a preparation, but generally, it is suitable to introduce D-mannitol into a human monoclonal antibody preparation by a dialytic method after substitution with a buffer solution suitable for a preparation by a gel filtration method. The concentration of D-mannitol in a D-mannitol solution usable for the dialytic method differs depending on the concentration of a human monoclonal antibody solution to be dialyzed, and for example is suitable in the range of generally 0.1 to 2% 50 (w/v), preferably 0.5 to 1.5% (w/v) in case the concentration of the human monoclonal antibody is 1 mg/ml, and suitable in the range of generally 0.1 to 10% (w/v), preferably 0.5 to 5% (w/v) in case the concentration of the human monoclonal antibody is 5 mg/ml.

The content of D-mannitol can be in the range of 1 to 20 mg, preferably 5 to 15 mg per 1 mg of the human monoclonal antibody in the preparation. When the content of D-mannitol is smaller than 1 mg, a 55 desired sufficient stabilization effect cannot be obtained, and when it is larger than 20 mg, agglutination of the antibody comes conversely to be observed.

Further, it was revealed that stability of the preparation was further enhanced by using glycine in addition to D-mannitol. Although the use quantity of glycine at that time is not strictly restricted, but it is

suitable that the use quantity is in the range of generally 0.005 to 0.2 mole, preferably 0.1 to 0.15 mole per 1 mg of the human monoclonal antibody.

Introduction of glycine into the preparation of this invention can be made at the same time of introduction of D-mannitol.

5 Further if necessary, it is possible to compound a suitable quantity of a phosphate salt or the like for adjustment of pH into the preparation of this invention.

**Example**

10 This invention is further specifically described below according to examples.

**Reference example 1 : Preparation of human monoclonal antibody**

Freezed cells of an antibody producing cell [human x human hybridoma = CLN H11 (ATCC HB 8307)]  
15 were thawed, and the thawed cells were washed with a basal medium and then cultured using a basal medium containing 10% fetal bovine serum. After culture, the cells were taken from this culture broth and cultured again in a serum-free medium (Hybrity-II, produced by HIH Biocenter Co. located at Kasai-shi, Hyogo-ken, Japan), and then scale up was made by batch culture in the same medium. Cells were removed from 40 liters of the resultant serum-free culture broth, and the resultant solution was concentrated  
20 to about 5 liters by ultrafiltration (PROSTAK™, produced by Millipore Co.).

Salting-out was carried out by adding ammonium sulfate to the concentrate so that the final concentration of the saturated solution became 70% to obtain a precipitate with ammonium sulfate.

This ammonium sulfate precipitate was dialyzed twice against 20 liters each of 10 mM phosphate buffer solution (hereafter referred to as PB) for total 24 hours, and then adsorbed on a cation exchange column (S-  
25 Sepharose, fast flow, produced by Pharmacia Co.). The column adsorbate was sufficiently washed with 10 mM PB, and then eluted by an NaCl concentration gradient from 0 to 0.5 M in 10 mM PB to obtain a rough fraction of IgG.

This was adsorbed on a Protein A column (produced by Repligen Co.), and after sufficient washing with 10 mM PB + 1 M NaCl, eluted with 0.1 M glycine-hydrochloric acid + 1 M NaCl (pH 3.0).

30 The resultant IgG was concentrated by ammonium sulfate fractionation (saturation concentration 50%), and the concentrate was subjected to gel filtration using a Sephacryl S-300 column (produced by Pharmacia Co.) equilibrated with 10 mM phosphate-buffered physiological saline (hereafter referred to as PBS) to obtain purified IgG.

35 **Reference example 2 : Preparation of stabilizer, etc.**

- (1) The phosphate-buffered physiological saline (PBS) was prepared by dissolving 1.15 g of  $\text{Na}_2\text{HPO}_4$  - (anhydrous), 8.0 g of NaCl, 0.2 g of  $\text{KH}_2\text{PO}_4$  and 0.2 g of KCl in about 900 ml of distilled water, adjusting the pH to 7.2 to 7.4, and making the total quantity 1.0 liter.
- 40 (2) As the physiological saline for injection was used one produced by Otsuka Pharmaceutical Co.
- (3) The mannitol solutions were prepared by diluting 20% (w/v) D-mannitol injection produced by Otsuka Pharmaceutical Co. with distilled water to concentrations of 1%, 5% and 10% (w/v), respectively.
- (4) 1% mannitol + physiological saline for injection was prepared by dissolving D-mannitol in physiological saline for injection to make the concentration 1% (w/v).
- 45 (5) The glycine-mannitol solution was prepared by dissolving 22.5 g of glycine, 50 ml of 20% D-mannitol solution and 1.58 g of  $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$  in about 900 ml of water and adjusting the pH to 7.2 to 7.4, and making the total quantity 1.0 liter.

**Example 1**

50 **Preparation and stability of freeze dried agents of a human monoclonal antibody - (1)**

The human monoclonal antibody solution prepared in Reference example 1 was dialyzed against each solution prepared in Reference example 2. The resultant each human monoclonal antibody solution was adjusted to each concentration of 1.0, 2.5 and 5.0 mg/ml. The resultant solutions were passed through a membrane filter of 0.22  $\mu\text{m}$ , and 1 ml portions thereof were poured into vials and freeze dried using a tray dryer produced by LABCONCO Co., USA. Freeze drying was made by holding the samples at a shelf temperature of -30°C for about three hour for freezing, and after complete freezing of the samples, starting

EP 0 597 101 A1

drying by moving a suction pump. The shelf temperature was raised to 0°C, and about 20 hours later, the freeze drying was finished.

1 ml portions of distilled water were added to the vials, respectively to dissolve freeze dried powders, and solubilities were compared based on OD<sub>600</sub> values usually used in measurement of the turbidity of culture broths of bacteria, etc. When insoluble particles were formed as a result of aggregation of the antibody, etc., OD<sub>600</sub> values increase. As a result, it was revealed, as shown in the following Table 1, that the 1% (w/v) mannitol solution and the glycine-mannitol solution are the best in view of solubility after freeze drying of the human monoclonal antibody. Further, even in case of the solutions of mannitol alone, the solubility went bad in the solutions having high concentrations of 5% and 10% (w/v). Further, even when the concentration of mannitol was 1% (w/v), existence in 0.9% or so of NaCl made the solubility worse, as shown in the result of 1% mannitol + physiological saline for injection.

Table 1

Stabilizer	Quantity (mg) of antibody in one vial			
	0	1.0	2.5	5.0
PBS	0.019	0.194	0.311	0.427
Physiological saline for injection	0.001	0.220	0.582	0.952
1% mannitol	0.001	0.014	0.035	-
5% mannitol	0.000	0.194	0.270	-
10% mannitol	0.001	0.246	0.317	-
1% mannitol + physiological saline for injection	0.001	0.193	0.228	-
Glycine-mannitol	0.010	0.042	-	0.115

Example 2

Preparation and stability of freeze dried agents of a human monoclonal antibody - (2)

According to the method described in Example 1, freeze dried agents were prepared containing in one vial 1, 2, 5, 10, 15, 20, 50 or 100 mg of D-mannitol and 1, 2.5 or 5 mg of the monoclonal antibody, and solubilities were compared. The results are shown in Table 2.

As a result, it was revealed that when the quantity of D-mannitol after freeze drying is in the range of 1 to 20 mg per 1 mg of the antibody, sufficient solubility can be obtained.

Table 2

Quantity (mg) of D-mannitol one vial	Quantity (mg) of antibody in one vial		
	1 mg	2.5 mg	5 mg
1	0.007	0.008	0.008
2	0.005	0.004	0.013
5	0.003	0.003	0.002
10	0.001	0.004	0.008
15	0.002	0.002	0.005
20	0.005	0.012	0.006
50	0.194	0.022	0.024
100	0.246	0.127	0.031

Industrial Applicability

As stated above, the human monoclonal antibody preparation of this invention is excellent in stability in a solution state, a freeze drying state and a freezing state, particularly stability against aggregation and precipitation of the human monoclonal antibody at the time of redissolution after freeze drying, and is useful as a medicinal drug.

Claims

- 10 1. A stabilized human monoclonal antibody preparation containing 1 to 20 mg of D-mannitol per 1 mg of a human monoclonal antibody.
- 15 2. The preparation according to claim 1 containing 5 to 15 mg of D-mannitol per 1 mg of the human monoclonal antibody.
- 16 3. The preparation according to claim 1 further containing glycine.
- 20 4. The preparation according to claim 3 containing 0.005 to 0.2 mole of glycine per 1 mg of the human monoclonal antibody.
- 25 5. The preparation according to claim 4 containing 0.1 to 0.15 mole of glycine per 1 mg of the human monoclonal antibody.
6. A process for preparation of the preparation according to claim 1 which comprises dialyzing the human monoclonal antibody in a buffer solution against a D-mannitol solution.

30

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/JP92/00914

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>1</sup>														
According to International Patent Classification (IPC) or to both National Classification and IPC														
Int. Cl <sup>5</sup> A61K39/395														
<b>II. FIELDS SEARCHED</b>														
Minimum Documentation Searched <sup>2</sup>														
<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 20%;">Classification System</th> <th style="width: 60%;">Classification Symbols</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">IPC</td> <td style="text-align: center;">A61K39/395</td> </tr> </tbody> </table>			Classification System	Classification Symbols	IPC	A61K39/395								
Classification System	Classification Symbols													
IPC	A61K39/395													
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>3</sup>														
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>4</sup></b>														
<table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category<sup>6</sup></th> <th style="width: 70%;">Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 20%;">Relevant to Claim No.<sup>13</sup></th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">X, Y</td> <td style="text-align: center;">JP, A, 63-88197 (Toso Corp.), April 19, 1988 (19. 04. 88), (Family: none)</td> <td style="text-align: center;">1-6</td> </tr> <tr> <td style="text-align: center;">X</td> <td style="text-align: center;">JP, A, 56-127320 (Mochida Pharmaceutical Co., Ltd.), October 6, 1981 (06. 10. 81), (Family: none)</td> <td style="text-align: center;">1-6</td> </tr> <tr> <td style="text-align: center;">Y</td> <td style="text-align: center;">JP, A, 53-47515 (The Green Closs Corp.), April 28, 1978 (28. 04. 78), (Family: none)</td> <td style="text-align: center;">3-5</td> </tr> </tbody> </table>			Category <sup>6</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X, Y	JP, A, 63-88197 (Toso Corp.), April 19, 1988 (19. 04. 88), (Family: none)	1-6	X	JP, A, 56-127320 (Mochida Pharmaceutical Co., Ltd.), October 6, 1981 (06. 10. 81), (Family: none)	1-6	Y	JP, A, 53-47515 (The Green Closs Corp.), April 28, 1978 (28. 04. 78), (Family: none)	3-5
Category <sup>6</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X, Y	JP, A, 63-88197 (Toso Corp.), April 19, 1988 (19. 04. 88), (Family: none)	1-6												
X	JP, A, 56-127320 (Mochida Pharmaceutical Co., Ltd.), October 6, 1981 (06. 10. 81), (Family: none)	1-6												
Y	JP, A, 53-47515 (The Green Closs Corp.), April 28, 1978 (28. 04. 78), (Family: none)	3-5												
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed														
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family														
<b>IV. CERTIFICATION</b>														
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Date of the Actual Completion of the International Search</td> <td style="width: 50%;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center;">September 21, 1992 (21. 09. 92)</td> <td style="text-align: center;">October 13, 1992 (13. 10. 92)</td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	September 21, 1992 (21. 09. 92)	October 13, 1992 (13. 10. 92)								
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
September 21, 1992 (21. 09. 92)	October 13, 1992 (13. 10. 92)													
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">International Searching Authority</td> <td style="width: 50%;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center;">Japanese Patent Office</td> <td></td> </tr> </table>			International Searching Authority	Signature of Authorized Officer	Japanese Patent Office									
International Searching Authority	Signature of Authorized Officer													
Japanese Patent Office														